A case of hepatitis C-associated osteosclerosis that was improved with the combination therapy of peginterferon alfa-2b and ribavirin

• Published in: Clinical journal of gastroenterology Vol. 4; no. 4; pp. 255 - 261
• Main Authors: Shakado, Satoshi, Akehi, Yuko, Yotsumoto, Kaoru, Fukunaga, Atsushi, Kuno, Shizuka, Tanaka, Takashi, Sakurai, Kunitoshi, Iwashita, Hideyuki, Ueda, Shuichi, Hirano, Genryu, Yokoyama, Keiji, Morihara, Daisuke, Nishizawa, Shinya, Sakamoto, Masaharu, Anan, Akira, Takeyama, Yasuaki, Irie, Makoto, Iwata, Kaoru, Sohda, Tetsuro, Sakisaka, Shotaro
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.08.2011
• Subjects: Abdominal Surgery; Case Report; Colorectal Surgery; Gastroenterology; Hepatology; Medicine; Medicine & Public Health; Surgical Oncology; Peginterferon alfa-2b; Ribavirin; Hepatitis C-associated osteosclerosis
• ISSN: 1865-7257; 1865-7265
• DOI: 10.1007/s12328-011-0228-7

Hepatitis C-associated osteosclerosis (HCAO) is a rare disorder characterized by a marked increase in skeletal mass in patients who are infected with hepatitis C virus (HCV). The clinical presentation is an acquired deep bone pain with increased serum alkaline phosphatase (ALP) activity. We present a case of a patient with HCAO who was treated with antiviral therapy. A 42-year-old Japanese man presented with severe, stabbing pain in his lower limbs. He was diagnosed with hepatitis C secondary to intravenous drug use 20 years earlier. Serum biochemical studies revealed markedly elevated ALP activity and osteocalcin levels. Skeletal radiographs showed diffuse bony sclerosis with marked cortical thickening in the long bones. The bony findings and clinical symptoms were attributed to HCAO. The HCV RNA viral load was high and the genotype was 2a. The patient was treated with peginterferon alfa-2b and ribavirin for 24 weeks. After 24 weeks of the combination therapy, the patient had a sustained virological response and clinical remission of bone pain and a decrease in the level of serum ALP. In conclusion, HCAO was improved by the combination therapy of peginterferon alfa-2b and ribavirin when the patient achieved sustained virological response. It was confirmed that HCAO was one of the extrahepatic manifestations of HCV.